Search Article Keyword:  

 PubMed Submission Abstract PDF  Cover Contents Editorial Board Count: 8899 Download Count: 1511 

ISSN 1007-9327 CN 14-1219/R  World J Gastroenterol  2008 December 7; 14(45): 6999-7004

CASE REPORT

Hydroxycut hepatotoxicity: A case series and review of liver toxicity from herbal weight loss supplements


Lily Dara, Jennifer Hewett, Joseph Kartaik Lim


Lily Dara, Department of Medicine, Griffin Hospital, Derby CT 06520, United States

Jennifer Hewett, Joseph Kartaik Lim, Section of Digestive Diseases, Yale University School of Medicine, New Haven CT 06520, United States

Author contributions: Dara L wrote the article; Hewett J and Lim JK critically revised the manuscript.

Correspondence to: Joseph Kartaik Lim, MD, Assistant Professor of Medicine, Director, Yale Viral Hepatitis Program, Yale Liver Center, Section of Digestive Diseases, Yale University School of Medicine, PO Box 208019, New Haven CT 06520, United States. joseph.lim@yale.edu

Telephone: +1-203-7376063  Fax: +1-203-7857273

Received: April 17, 2008       Revised: June 2, 2008

Accepted: June 9, 2008

Published online: December 7, 2008

  

Abstract

Dietary supplements represent an increasingly common source of drug-induced liver injury. Hydroxycut is a popular weight loss supplement which has previously been linked to hepatotoxicity, although the individual chemical components underlying liver injury remain poorly understood. We report two cases of acute hepatitis in the setting of Hydroxycut exposure and describe possible mechanisms of liver injury. We also  comprehensively review and summarize the existing literature on commonly used weight loss supplements, and their individual components which have demonstrated potential for liver toxicity. An increased effort to screen for and educate patients and physicians about supplement-associated hepatotoxicity is warranted.

 

© 2008 The WJG Press. All rights reserved.

 

Key words: Hydroxycut; Dietary supplements; Liver; Liver failure; Toxicity; Weight loss; Medicine; Hepatitis

 

Peer reviewer: Frank A Anania, Professor, Emory University School of Medicine, Division of Digestive Diseases, 615 Michael Street, Room 255 Whitehead Biomedical Research Building, Atlanta GA 30322, United States

 

Dara L, Hewett J, Lim JK. Hydroxycut hepatotoxicity: A case series and review of liver toxicity from herbal weight loss supplements. World J Gastroenterol 2008; 14(45): 6999-7004  Available from: URL: http://www.wjgnet.com/1007-9327/14/6999.asp  DOI: http://dx.doi.org/10.3748/wjg.14.6999

 

INTRODUCTION

Obesity has become an increasingly important public health problem in the United States. Recent data show that more than 30% of adults are obese and 65% overweight[1]. The use of dietary supplements for weight loss has become increasingly popular, as reflected by the $55.4 billion spent in the U.S. in 2006 for weight loss and diet control[2,3]. Based on a study by the National Center for Complementary and Alternative Medicine (NCCAM), 36% of adults are using some form of complementary or alternative medicine, which rises to 62% when including megavitamins or prayer. Although dietary and herbal supplements are governed under the DSHEA act of 1994, they are not presently regulated by the U.S. Federal Drug Administration, and the safety profiles of many are unknown. An increasing number of case reports have emerged which suggest causative supplement-associated liver toxicity. Hydroxycut is an herbal weight loss supplement that has been suspected to have possible liver toxicity. Herein we present two patients who experienced severe acute hepatitis in the setting of documented Hydroxycut exposure, and without alternative etiology after comprehensive serologic liver evaluation.

 

CASE REPORTS

Case 1

A 40-year-old female with a prior medical history notable only for hypothyroidism and diet-controlled hyperlipidemia presented to the Emergency Department with 3 d of new-onset crampy, mid-epigastric abdominal pain and non-bloody diarrhea. She noted subjective fevers and chills, and two isolated episodes of nausea and vomiting, anorexia and profound fatigue. She did not experience jaundice, icterus, pruritus, arthralgias, acholic stools or dark urine. One week prior to presentation, she began using Hydroxycut, 6 pills daily in preparation for a bodybuilding competition. Just prior to presentation she attended an office holiday party, although no other persons in attendance became ill. She did not smoke or drink. She otherwise does not take regular medications except for levothyroxine. She denied taking any other supplements or alternative medications. She was afebrile with stable vital signs, and normal body mass index. Her exam was notable only for mild mid-epigastric tenderness to palpation. She had no liver enlargement and no stigmata of chronic liver disease. Her laboratory profile on admission revealed an acute hepatitis with AST 1020 U/L and ALT 1150 U/L, total bilirubin 0.67 mg/dL, alkaline phosphatase 299 U/L, INR 0.96, white cell count 5.9 × 103/mL, hemoglobin 11.9 g/dL, platelet count 228/mL, and creatinine 0.9 mg/dL. Diagnostic evaluation was negative for hepatitis A, B, C, cytomegalovirus and Epstein-Barr virus, autoimmune liver disorders (ANA, ASMA), alpha-1 anti-trypsin deficiency, and ehrlichiosis. On day 2 of admission, her transaminases decreased to AST 399 U/L and ALT 647 U/L. On day 3, she was clinically well and discharged from the hospital. Upon outpatient follow-up, she had returned to her usual state of health with normalization of transaminases with AST 46 U/L and ALT 48 U/L. She has not experienced any further recurrence of symptoms or liver abnormalities within 10 mo of follow-up.

 

Case 2

A 33-year-old female with a prior medical history of a pituitary adenoma presented to the Emergency Department with 1 mo of new-onset jaundice. She reported a flu-like illness of 2 wk duration with nausea and crampy abdominal pain and began to experience jaundice, acholic stools, dark-colored urine, pruritus, and profound fatigue. These symptoms appeared to be improving during the week prior to admission except for worsening jaundice and fatigue. She noted that during the month prior to admission, she had taken Hydroxcut supplements for 2 wk to help achieve weight loss, but discontinued this medication upon onset of symptoms. She additionally reported eating lobster during the month prior to admission, but could not recall other individuals who became ill. Her only medication was Ortho-Novum contraceptive, which she had been taking for 2.5 years. Her social history was unremarkable without regular alcohol ingestion, and the absence of risk factors for chronic viral hepatitis. She was afebrile with stable vital signs, and normal body mass index. Her exam was notable only for jaundice and scleral icterus. She had no liver enlargement and no stigmata of chronic liver disease. Her laboratory profile at admission was notable for acute hepatitis with AST 934 U/L and ALT 1 570 U/L, total bilirubin 20.9 mg/dL, direct bilirubin 14.2 mg/dL, alkaline phosphatase 112 U/L, INR 1.08, white cell count 9.2 × 103/mL, hematocrit 42%, platelet count 414/mL, creatinine 0.8 mg/dL. Diagnostic evaluation was negative for hepatitis A, B, C, cytomegalovirus, Epstein-Barr virus, and herpes simplex virus infections. Her autoimmune profile revealed low titer increase in anti-nuclear antibody (ANA) and anti-smooth muscle antibody (ASMA) suggestive of an immune-mediated drug-induced hepatitis. Her jaundice eventually resolved and her liver function normalized.

 

DISCUSSION

The public’s increasing demand for alternative medicine, the newly found global interest in phytomedicine and herbal therapies, the rising cost of conventional prescription drugs, and a loss of faith in Western medicine, have led to a rapid rise in the use of unregulated herbal supplements and therapies. An estimated 80% of the world population uses herbal medicines, largely outside the U.S.[4]. In a study performed at an outpatient liver clinic, over 21% of patients were taking herbal supplements in the setting of chronic liver disease[5]. The FDA describes dietary supplements as a product taken by mouth that contains a “dietary ingredient” intended to supplement the diet. The “dietary ingredients” in these products may include: vitamins, minerals, herbs or other botanicals, amino acids, and substances such as enzymes, organ tissues, glandulars, and metabolites. Most of these products have not been rigorously studied through placebo-controlled, blinded, randomized

trials[6].

Hydroxycut is one of the most popular dietary supplements for weight loss on the market today, including two formulations Hydroxycut and Hydroxycut hardcore. Hydroxycut contains several different herbs, including: Garcinia Cambogia extract, chromium polynicotinate, Gymnema sylvestre extract and Camellia Sinenesis (C. Sinenesis) (Table 1). Both patients in this report used the dietary supplement Hydroxycut within a short time frame before presenting with acute hepatitis, suggesting Hydroxycut as the most likely etiology for acute liver injury. Neither patient had a history suggestive of other exposures or risk factors for viral hepatitis, alcoholic hepatitis, other toxin-mediated injury, or chronic liver disease. A comprehensive serologic and radiographic evaluation performed in both patients did not reveal alternative sources for liver toxicity. Although causation is difficult to confirm in cases of suspected drug-associated hepatotoxicity, the temporal relationship to acute liver injury and rapid resolution upon withdrawal of Hydroxycut make this likely. Hydroxycut has previously been associated with both a cholestatic and hepatocellular pattern of injury. The specific components likely implicated in liver toxicity include G. Cambogia, Chromium, and green tea root extract (Camellia Sinensis) based on prior data suggesting liver toxicity.  Patient 1 experienced a more typical hepatocellular pattern of injury, patient 2 demonstrated an immune-mediated pattern of injury, which has not previously been described.

There has been one prior report of two cases of possible hepatotoxicity with Hydroxycut in the literature[7]; both cases were young males who had documented periods of Hydroxycut exposure and experienced similar clinical syndromes marked by fatigue, jaundice, and pruritus with marked hepatocellular or cholestatic pattern and complete resolution upon supplement withdrawal. Our case series validates the likely causative relationship between Hydroxycut exposure and liver toxicity, and further suggests that an autoimmune pattern of hepatotoxicity may be observed. Although less common, drug-associated autoimmune hepatitis has been reported in several herbal supplements including Greater Celadine, Dai-Saiko-To, and Black Cohosh. Herein we review key ingredients of Hydroxycut that have been implicated in liver toxicity.

G. Cambogia is a fruit native to southeastern Asia and western Africa used to make meals more “filling”[8]. Its main component hydroxycitric acid (HCA) is an inhibitor of the citrate cleavage enzyme (ATP citrate lyase) blocking de novo synthesis of fatty acids[9]. HCA was initially studied in rodents for the dietary treatment of obesity and the results seemed to be promising. Unfortunately randomized controlled trials in humans for this purpose showed very conflicting results. Nevertheless, HCA is a primary component of many weight loss supplements in the market, and similar to others in its class, the toxicity profile is poorly studied. In the recent literature  a case of fatal liver failure was reported in a patient taking HCA and montelukast suggesting the synergistic hepatotoxic effect of these two agents[10]. There have also been reports of G. Cambogia toxicity by the WHO database, mostly describing an increase in hepatic enzymes[6].

Chromium is an essential trace element and cofactor to insulin most commonly occurring in hexavalent () and trivalent () states. The hexavalent form is found in the dye and leather industry and is responsible for occupational toxicity ranging from dermatitis to lung cancer[11]. In 1989, the National Academy of Sciences established an “estimated safe and adequate daily dietary intake” range for chromium of 50 to 200 mg[12]. In 2001 the Institute of Medicine and the National Academy of Sciences established Dietary Reference Intakes (DRI) for Chromium, ranging from 0.2 mg for infants to a maximum of 45 mg in lactating mothers[13]. Chromium is used in weight loss supplements due to purported effects of decreasing body fat and increasing basal metabolic rate[14,15]. A recent meta-analysis of available RCTs concluded that weight reduction with chromium although statistically significant was not clinically meaningful[2]. There have been case reports of chromium toxicity causing acute hepatitis, thrombocytopenia and renal failure due to both environmental[16,17] and dietary supplements[18]. Although renal failure requiring dialysis is a more common concern[19], those presenting with liver toxicity frequently elaborate aminotransferase elevations greater than 1000 mg/dL. Each Hydroxycut serving contains 133 mg of Chromium, which is taken three times daily, resulting in a cumulative daily consumption grater than twice the NAS safe maximum dose.

Camellia Sinensis is the scientific name for green tea, which is widely regarded by the public as safe, and commonly incorporated into supplements due to purported anti-cancer potential[20], weight reduction[21] and antioxidant properties[22]. Acute hepatotoxicity from C. Sinensis is well-described, and may range from acute hepatitis to acute liver failure. Based on 17 published cases in the literature[23-27], most cases appear to occur following large ingestions of green tea, with resolution following withdrawal, and recurrence with re-challenge[28]. Consequently, C. Sinesis has been banned in France and Spain, although it remains unregulated in weight loss supplements commercially available in the U.S.

Other Hydroxycut components for which liver toxicity have not been described include Gymnema Sylvestre, Rhodiola Rosea, and Withania Somnifera. Gymnema Sylvestre has been used to control hyperglycemia[29] and hyperlipidemia[30] in rats. Toxicity studies in rodents have not shown hepatotoxicity[31] and no case report of liver injury has been reported. Rhodiola Rosea extract is used to decrease fatigue[32] and improve exercise tolerance[33]. Withania Somnifera has been used for its anti-inflammatory properties[34,35]. Neither R Rosea or W Somnifera have been associated with liver toxicity, although W Somnifera may result in renal impairment in rats[36].

Of note, the more concentrated Hydroxycut Hard Core product contains additional herbal formulations such as White Willow extract and Yohimbine. These have not been demonstrated to result in liver injury, whereas Willow bark extract may have anti-inflammatory effects in vitro, this was not observed in patients with rheumatoid arthritis or osteoarthritis in a randomized controlled trial[37]. Yohimbine is an indole alkaloid from the bark of the African Pausinystalia Yohimbe, and serves as an alpha-2 receptor antagonist which may treat male impotence[38]. Although nausea, vomiting and abdominal pain have been described, liver toxicity has not been observed.

The FDA has issued warnings on several herbal supplements known to have hepatotoxic potential including Comfrey (2001), Kava (2002) and the dietary supplement Lipokinetix (2001). This review does not seek to provide a comprehensive review of all known hepatotoxins, but highlight a short list of ingredients within best selling weight loss supplements which have been demonstrated to have hepatotoxic potential.

Ephedra alkaloid, AKA Ma Huang, is the most commonly used weight loss supplement in the U.S.[4], and is well-known to have potentially deleterious cardiovascular and CNS effects[39], but has also been implicated in numerous cases of liver failure[40,41]. As such, dietary supplements containing ephedra were banned in the U.S. in April 2004[42], but remain widely available through unregulated internet sources in various forms, including the supplement Leptoprin (previously Anorex) which contains 20 mg of ephedrine, 200 mg of caffeine, 324 mg of aspirin, and unknown amounts of Green tea and cayenne. Adipokinitex came to the market to replace Lipokinetix which was removed in 2002 by Syntrax Innovations Inc. due to FDA warnings regarding reported cases of hepatotoxicity[43]. Although the Usnic acid has been removed from the formulation, this diet pill still contains Norephedrine or Norphenephrine and Green tea extracts. Ephedrasil Hardcore, a top selling diet pill, is a newer formulation of Ephedra following its ban in 2004, and contains  many ingredients including Chromium, Yohimbine, and green tea extract.

Hoodia Gordoni, a popular supplement used for appetite suppression, and is derived from a cactus-like bush leaf native to southern Africa. Although initially isolated by Pfizer in the 1970s, research was discontinued due to liver toxicity found in early research studies. Despite these reports, this is a common ingredient in dietary supplements such as Slim-Citi, Trim Spa X32 and Ephedrine-P57.

Zalestrim is another top selling supplement composed of green tea and Black Cohosh, which are described above as known sources of potential hepatotoxicity[44-48]. It also contains Dong Quai, which increases prothrombin time and thereby increases bleeding risk[49].

In summary, this case series and review of the literature highlight the potential hepatotoxicity of commonly used herbal supplements including Hydroxycut. Due to their loose regulation in the current drug marketplace, oversight of their use by physicians and regulators alike remains poor. Those supplements with potential liver toxicity are summarized in Tables 2 and 3, although further investigation is needed to better clarify the mechanisms and patterns of injury, and inform policy makers on those ingredients which require more vigorous regulation. The use of supplements is frequently not queried by physicians, and may not be reported in the same manner as prescription drugs by patients. As such, it is advisable that physicians ask specifically about the use of non-prescription drugs and supplements, warn patients with known liver disease about the potential consequences of their use, and to query patients specifically about possible supplement exposure in cases of acute or chronic liver injury. Increased attention to this issue by physicians and regulatory agencies may lead to more successful efforts to decrease the burden of drug-associated liver injury in the U.S.

 

REFERENCES

1      National Center for Health Statistics. Prevalence of Overweight and Obesity Among Adults: United States, 1999-
        2002. Available from: URL: http://www.cdc.gov/nchs/products/pubs/pubd/hestats/obese/obse99.htm

2      Blanck HM, Khan LK, Serdula MK. Use of nonprescription weight loss products: results from a multistate survey. JAMA
        2001; 286: 930-935  
PubMed   DOI

3      Miles J, Petrie C, Steel M. Slimming on the Internet. J R Soc Med 2000; 93: 254-257   PubMed

4      Farnsworth NR, Akerele O, Bingel AS, Soejarto DD, Guo Z. Medicinal plants in therapy. Bull World Health Organ 1985;
        63: 965-981  
PubMed

5      Stickel F, Patsenker E, Schuppan D. Herbal hepatotoxicity. J Hepatol 2005; 43: 901-910   PubMed   DOI

6      Pittler MH, Ernst E. Dietary supplements for body-weight reduction: a systematic review. Am J Clin Nutr 2004; 79: 529-
        536  
PubMed

7      Stevens T, Qadri A, Zein NN. Two patients with acute liver injury associated with use of the herbal weight-loss
        supplement hydroxycut. Ann Intern Med 2005; 142: 477-478  
PubMed

8      Burdock G, Soni M, Bagchi M, Bagchi D. Garcinia cambogia toxicity is misleading. Food Chem Toxicol 2005; 43: 1683-
        1684; author reply 1685-1686  
PubMed   DOI

9      Heymsfield SB, Allison DB, Vasselli JR, Pietrobelli A, Greenfield D, Nunez C. Garcinia cambogia (hydroxycitric acid) as a
        potential antiobesity agent: a randomized controlled trial. JAMA 1998; 280: 1596-1600  
PubMed   DOI

10    Actis GC, Bugianesi E, Ottobrelli A, Rizzetto M. Fatal liver failure following food supplements during chronic treatment
        with montelukast. Dig Liver Dis 2007; 39: 953-955  
PubMed   DOI

11    Katz SA, Salem H. The toxicology of chromium with respect to its chemical speciation: a review. J Appl Toxicol 1993;
        13: 217-224  
PubMed   DOI

12    National Research Council (U.S.). Subcommittee on the Tenth Edition of the RDAs, National Institutes of Health (U.S.),
        National Research Council (U.S.). Committee on Dietary Allowances. Recommended dietary allowances. 10th rev. ed.
        Washington, D.C.: National Academy Press, 1989: 241-243 

13    Institute of Medicine FaNB, ebrary Inc. DRI. dietary reference intakes for vitamin A, vitamin K, arsenic, boron,
        chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc: a report of the Panel on
        Micronutrients ... and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and
        Nutrition Board, Institute of Medicine. 2001: xxii, 773 p. Available from: URL: http://site.ebrary.com/lib/yale/Doc?
        id=10032471

14    Anderson RA. Essentiality of chromium in humans. Sci Total Environ 1989; 86: 75-81   PubMed   DOI

15    Anderson RA. Effects of chromium on body composition and weight loss. Nutr Rev 1998; 56: 266-270   PubMed

16    Fristedt B, Lindqvist B, Schuetz A, Ovrum P. Survival in a case of acute oral chromic acid poisoning with acute renal
        failure treated by haemodialysis. Acta Med Scand 1965; 177: 153-159  
PubMed 

17    van Heerden PV, Jenkins IR, Woods WP, Rossi E, Cameron PD. Death by tanning--a case of fatal basic chromium
        sulphate poisoning. Intensive Care Med 1994; 20: 145-147  
PubMed   DOI

18    Cerulli J, Grabe DW, Gauthier I, Malone M, McGoldrick MD. Chromium picolinate toxicity. Ann Pharmacother 1998; 32:
        428-431  
PubMed   DOI

19    Wasser WG, Feldman NS, D’Agati VD. Chronic renal failure after ingestion of over-the-counter chromium picolinate. Ann
        Intern Med 1997; 126: 410  
PubMed 

20    Yang CS, Yang GY, Chung JY, Lee MJ, Li C. Tea and tea polyphenols in cancer prevention. Adv Exp Med Biol 2001; 492:
        39-53  
PubMed 

21    Shixian Q, VanCrey B, Shi J, Kakuda Y, Jiang Y. Green tea extract thermogenesis-induced weight loss by epigallocatechin
        gallate inhibition of catechol-O-methyltransferase. J Med Food 2006; 9: 451-458  
PubMed   DOI

22    Coimbra S, Castro E, Rocha-Pereira P, Rebelo I, Rocha S, Santos-Silva A. The effect of green tea in oxidative stress.
        Clin Nutr 2006; 25: 790-796  
PubMed   DOI

23    Abu el Wafa Y, Benavente Fernandez A, Talavera Fabuel A, Perez Ramos MA, Ramos-Clemente JI. [Acute hepatitis
        induced by Camellia sinensis (green tea)] An Med Interna 2005; 22: 298  
PubMed

24    Duenas Sadornil C, Fabregas Puigtio S, Durandez R. [Hepatotoxicity due to Camelia sinensis] Med Clin (Barc) 2004;
        122: 677-678  
PubMed   DOI

25    Garcia-Moran S, Saez-Royuela F, Gento E, Lopez Morante A, Arias L. [Acute hepatitis associated with Camellia thea
        and Orthosiphon stamineus ingestion] Gastroenterol Hepatol 2004; 27: 559-560  
PubMed   DOI

26    Gloro R, Hourmand-Ollivier I, Mosquet B, Mosquet L, Rousselot P, Salame E, Piquet MA, Dao T. Fulminant hepatitis
        during self-medication with hydroalcoholic extract of green tea. Eur J Gastroenterol Hepatol 2005; 17: 1135-1137

        PubMed   DOI

27    Molinari M, Watt KD, Kruszyna T, Nelson R, Walsh M, Huang WY, Nashan B, Peltekian K. Acute liver failure induced by
        green tea extracts: case report and review of the literature. Liver Transpl 2006; 12: 1892-1895  
PubMed   DOI

28    Bonkovsky HL. Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann
        Intern Med 2006; 144: 68-71  
PubMed 

29    Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS. Systematic review of herbs and dietary supplements for glycemic
        control in diabetes. Diabetes Care 2003; 26: 1277-1294  
PubMed   DOI

30    Luo H, Kashiwagi A, Shibahara T, Yamada K. Decreased bodyweight without rebound and regulated lipoprotein
        metabolism by gymnemate in genetic multifactor syndrome animal. Mol Cell Biochem 2007; 299: 93-98  
PubMed   DOI

31    Ogawa Y, Sekita K, Umemura T, Saito M, Ono A, Kawasaki Y, Uchida O, Matsushima Y, Inoue T, Kanno J. [Gymnema
        sylvestre leaf extract: a 52-week dietary toxicity study in Wistar rats] Shokuhin Eiseigaku Zasshi 2004; 45: 8-18

        PubMed 

32    Darbinyan V, Kteyan A, Panossian A, Gabrielian E, Wikman G, Wagner H. Rhodiola rosea in stress induced fatigue--a
        double blind cross-over study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental
        performance of healthy physicians during night duty. Phytomedicine 2000; 7: 365-371  
PubMed

33    De Bock K, Eijnde BO, Ramaekers M, Hespel P. Acute Rhodiola rosea intake can improve endurance exercise
        performance. Int J Sport Nutr Exerc Metab 2004; 14: 298-307  
PubMed

34    Rasool M, Varalakshmi P. Immunomodulatory role of Withania somnifera root powder on experimental induced
        inflammation: An in vivo and in vitro study. Vascul Pharmacol 2006; 44: 406-410  
PubMed   DOI

35    Spelman K, Burns J, Nichols D, Winters N, Ottersberg S, Tenborg M. Modulation of cytokine expression by traditional
        medicines: a review of herbal immunomodulators. Altern Med Rev 2006; 11: 128-150  
PubMed  

36    Arseculeratne SN, Gunatilaka AA, Panabokke RG. Studies of medicinal plants of Sri Lanka. Part 14: Toxicity of some
        traditional medicinal herbs. J Ethnopharmacol 1985; 13: 323-335  
PubMed   DOI

37    Biegert C, Wagner I, Ludtke R, Kotter I, Lohmuller C, Gunaydin I, Taxis K, Heide L. Efficacy and safety of willow bark
        extract in the treatment of osteoarthritis and rheumatoid arthritis: results of 2 randomized double-blind controlled trials.
        J Rheumatol 2004; 31: 2121-2130  
PubMed 

38    Thomas C. Westfall and David P. Westfall. Adrenergic receptor antagonist: Yohimbine. In: Goodman LS, Gilman A,
        Gilman AG, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: The McGraw-
        Hill Companies, Inc, 2006: 271  
DOI

39    Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements
        containing ephedra alkaloids. N Engl J Med 2000; 343: 1833-1838  
PubMed   DOI

40    Borum ML. Fulminant exacerbation of autoimmune hepatitis after the use of ma huang. Am J Gastroenterol 2001; 96:
        1654-1655  
PubMed   DOI

41    Nadir A, Agrawal S, King PD, Marshall JB. Acute hepatitis associated with the use of a Chinese herbal product, ma-
        huang. Am J Gastroenterol 1996; 91: 1436-1438  
PubMed  

42    US Food and Drug Administration. FDA Issues Regulation Prohibiting Sale of Dietary Supplements Containing
        Ephedrine Alkaloids and Reiterates Its Advice That Consumers Stop Using These Products. 2004 [cited 2007 8th
        November]; Available from: URL: http://www.fda.gov/bbs/topics/NEWS/2004/NEW01021.html

43    Administration UFaD. Letter to Distributor on Hazardous Dietary Supplement LipoKinetix. 2001 [cited 2007 8th
        November]; Available from: URL: http://www.cfsan.fda.gov/~dms/ds-ltr26.html

44    Cohen SM, O’Connor AM, Hart J, Merel NH, Te HS. Autoimmune hepatitis associated with the use of black cohosh: a
        case study. Menopause 2004; 11: 575-577  
PubMed   DOI

45    Levitsky J, Alli TA, Wisecarver J, Sorrell MF. Fulminant liver failure associated with the use of black cohosh. Dig Dis Sci
        2005; 50: 538-539  
PubMed   DOI

46    Lontos S, Jones RM, Angus PW, Gow PJ. Acute liver failure associated with the use of herbal preparations containing
        black cohosh. Med J Aust 2003; 179: 390-391  
PubMed 

47    Mahady GB. Black cohosh (Actaea/Cimicifuga racemosa): review of the clinical data for safety and efficacy in
        menopausal symptoms. Treat Endocrinol 2005; 4: 177-184  
PubMed 

48    Whiting PW, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust
        2002; 177: 440-443  
PubMed

49    Stedman C. Herbal hepatotoxicity. Semin Liver Dis 2002; 22: 195-206   PubMed   DOI

50    Larrey D, Pageaux GP. Hepatotoxicity of herbal remedies and mushrooms. Semin Liver Dis 1995; 15: 183-188

        PubMed 

51    Lynch CR, Folkers ME, Hutson WR. Fulminant hepatic failure associated with the use of black cohosh: a case report.
        Liver Transpl 2006; 12: 989-992  
PubMed   DOI

52    Huntley A. The safety of black cohosh (Actaea racemosa, Cimicifuga racemosa). Expert Opin Drug Saf 2004; 3: 615-
        623  
PubMed   DOI

53    Mokhobo KP. Herb use and necrodegenerative hepatitis. S Afr Med J 1976; 50: 1096-1099   PubMed 

54    Sheikh NM, Philen RM, Love LA. Chaparral-associated hepatotoxicity. Arch Intern Med 1997; 157: 913-919   PubMed 

        DOI

55    Nadir A, Reddy D, Van Thiel DH. Cascara sagrada-induced intrahepatic cholestasis causing portal hypertension: case
        report and review of herbal hepatotoxicity. Am J Gastroenterol 2000; 95: 3634-3637  
PubMed   DOI

56    Larrey D, Vial T, Pauwels A, Castot A, Biour M, David M, Michel H. Hepatitis after germander (Teucrium chamaedrys)
        administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med 1992; 117: 129-132  
PubMed

57    Mostefa-Kara N, Pauwels A, Pines E, Biour M, Levy VG. Fatal hepatitis after herbal tea. Lancet 1992; 340: 674

        PubMed   DOI

58    Benninger J, Schneider HT, Schuppan D, Kirchner T, Hahn EG. Acute hepatitis induced by greater celandine
        (Chelidonium majus). Gastroenterology 1999; 117: 1234-1237  
PubMed   DOI

59    Stickel F, Poschl G, Seitz HK, Waldherr R, Hahn EG, Schuppan D. Acute hepatitis induced by Greater Celandine
        (Chelidonium majus). Scand J Gastroenterol 2003; 38: 565-568  
PubMed   DOI

60    Woolf GM, Petrovic LM, Rojter SE, Wainwright S, Villamil FG, Katkov WN, Michieletti P, Wanless IR, Stermitz FR, Beck JJ,
        Vierling JM. Acute hepatitis associated with the Chinese herbal product jin bu huan. Ann Intern Med 1994; 121: 729-735

        PubMed  

61    Escher M, Desmeules J, Giostra E, Mentha G. Hepatitis associated with Kava, a herbal remedy for anxiety. BMJ 2001;
        322: 139  
PubMed   DOI

62    Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. Ann Intern Med 2001; 135: 68-69   PubMed  

63    Stickel F, Baumuller HM, Seitz K, Vasilakis D, Seitz G, Seitz HK, Schuppan D. Hepatitis induced by Kava (Piper
        methysticum rhizoma). J Hepatol 2003; 39: 62-67  
PubMed   DOI

64    Millonig G, Stadlmann S, Vogel W. Herbal hepatotoxicity: acute hepatitis caused by a Noni preparation (Morinda
        citrifolia). Eur J Gastroenterol Hepatol 2005; 17: 445-447  
PubMed   DOI

65    Galloway JH, Marsh ID, Bittiner SB, Messenger AG, Gawkrodger DJ, Glet R, Forrest AR. Chinese herbs for eczema, the
        active compound? Lancet 1991; 337: 566  
PubMed   DOI

66    Anderson IB, Mullen WH, Meeker JE, Khojasteh-BakhtSC, Oishi S, Nelson SD, Blanc PD. Pennyroyal toxicity:
        measurement of toxic metabolite levels in two cases and review of the literature. Ann Intern Med 1996; 124: 726-734

        PubMed 

67    Bakerink JA, Gospe SM Jr, Dimand RJ, Eldridge MW. Multiple organ failure after ingestion of pennyroyal oil from herbal
        tea in two infants. Pediatrics 1996; 98: 944-947  
PubMed 

68    Seybold U, Landauer N, Hillebrand S, Goebel FD. Senna-induced hepatitis in a poor metabolizer. Ann Intern Med 2004;
        141: 650-651  
PubMed 

69    Itoh S, Marutani K, Nishijima T, Matsuo S, Itabashi M. Liver injuries induced by herbal medicine, syo-saiko-to (xiao-chai-
        hu-tang). Dig Dis Sci 1995; 40: 1845-1848  
PubMed   DOI

70    Durazo FA, Lassman C, Han SH, Saab S, Lee NP, Kawano M, Saggi B, Gordon S, Farmer DG, Yersiz H, Goldstein RL,
        Ghobrial M, Busuttil RW. Fulminant liver failure due to usnic acid for weight loss. Am J Gastroenterol 2004; 99: 950-952

        PubMed   DOI

71    Sanchez W, Maple JT, Burgart LJ, Kamath PS. Severe hepatotoxicity associated with use of a dietary supplement
        containing usnic acid. Mayo Clin Proc 2006; 81: 541-544  
PubMed 

72    Mennecier D, Saloum T, Dourthe PM, Bronstein JA, Thiolet C, Farret O. [Acute hepatitis after phytotherapy] Presse Med
        1999; 28: 966  
PubMed 

 

S- Editor  Li DL    L- Editor  Ma JY    E- Editor  Ma WH

 

 

 

 

 

Reviews Add
more>>


Related Articles:
Hepatoxicity associated with weight-loss supplements: A case for better post-marketing surveillance
Hydroxycut hepatotoxicity: A case series and review of liver toxicity from herbal weight loss supplements
more>>